NCT05515783 is a Phase 1, PHASE2 clinical trial of 68Ga-FAP-RGD in Tumor, sponsored by First Affiliated Hospital of Fujian Medical University.

Who is sponsoring NCT05515783?

NCT05515783 is sponsored by First Affiliated Hospital of Fujian Medical University.

What drugs are being tested in NCT05515783?

Interventions in NCT05515783: 68Ga-FAP-RGD, 68Ga-FAP-RGD.

Is NCT05515783 still recruiting?

NCT05515783 is currently status unknown. Last updated 21 September 2023.

Last reviewed 2023-09-21 · How we verify

NCT05515783

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-FAP-RGD PET/CT : Dosimetry and Preliminary Clinical Translational Studies

Status unknown Phase 1, PHASE2 Last updated 21 September 2023

What this trial tests

Phase 1, PHASE2 trial testing 68Ga-FAP-RGD in Tumor in 50 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
1 May 2024

1 May 2024

Quick facts

Lead sponsor	First Affiliated Hospital of Fujian Medical University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	1 May 2022
Primary completion	1 May 2024
Estimated completion	1 May 2024
Sites	1 location across China

Drugs / interventions tested

68Ga-FAP-RGD — full drug profile →
68Ga-FAP-RGD — full drug profile →

Conditions studied

Tumor — all drugs for Tumor →

Sponsor

First Affiliated Hospital of Fujian Medical University

Who can join

18 and older, any sex, with Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As an new dual targeting PET radiotracer, 68Ga-FAP-RGD is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAP-RGD in patients with various types of cancer and compared them with the results of 68Ga-FAPI-02 or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAP-RGD.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin-RGD interactions.
Javid H, Oryani MA, Rezagholinejad N, Esparham A, et al · · 2024 · cited 137× · PMID 38349028 · DOI 10.1002/cam4.6800
Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD.
Zang J, Wen X, Lin R, Zeng X, et al · · 2022 · cited 69× · PMID 36276644 · DOI 10.7150/thno.79144
Theranostics in targeting fibroblast activation protein bearing cells: Progress and challenges.
Rezaei S, Gharapapagh E, Dabiri S, Heidari P, et al · · 2023 · cited 17× · PMID 37481033 · DOI 10.1016/j.lfs.2023.121970
Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.
Wu Y, Wang X, Sun X, Gao X, et al · · 2025 · cited 7× · PMID 41049753 · DOI 10.1016/j.apsb.2025.07.009
[68Ga]Ga-LNC1007 versus 2-[18F]FDG in the evaluation of patients with metastatic differentiated thyroid cancer: a head-to-head comparative study.
Chen Y, Zheng S, Zang J, Shao Z, et al · · 2025 · cited 2× · PMID 39404790 · DOI 10.1007/s00259-024-06930-4

Verify or expand the search:

Other recruiting trials for Tumor

Currently open trials in the same condition.

NCT07399652 — Artificial Intelligence-Guided Detection of Blood Vessels to Enhance Safety in Third-Space Endoscopic Procedures · NA · recruiting
NCT07382752 — Decoupling Immunotherapy Toxicity and Cancer Response · recruiting
NCT07464132 — Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases · Phase 1, PHASE2 · recruiting
NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
NCT07147465 — Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for On · recruiting

Other First Affiliated Hospital of Fujian Medical University trials

Trials by the same sponsor.

NCT07513844 — Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease · NA · not yet recruiting
NCT07337772 — Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty · NA · recruiting
NCT07369401 — Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory · NA · not yet recruiting
NCT07378358 — Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study · recruiting
NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05515783 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Fujian Medical University
Last refreshed: 21 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05515783.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing